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Figure 8
** **
	 50	
the	RNA	level	by	RT-PCR.	(C)	Balb/c	mice	were	injected	with	1x105	RENCA-luc	cells	
infected	with	a	non-silencing	lentivirus,	or	CCR4	shRNA	(shCCR4),	and	treated	twice	
weekly	with	Affi-5	at	10	mg/kg	(T)	or	isotype	control	(C),	starting	48h	after	surgery,	n=6	
for	each	group.	Mice	were	sacrificed	17	days	after	surgery	and	tumor	weight	was	
recorded.	Affi-5	treatment	had	an	effect	(two-way	ANOVA,	p=	0.0036),	and	CCR4	
silencing	did	not	interact	significantly	with	the	Affi-5	treatment	(p=0.64).	
	
	
	
	
